GOLIMUMAB: A HUMAN MONOCLONAL ANTIBODY AGAINST TUMOUR NECROSIS FACTOR-a FOR THE RHEUMATOID ARTHRITIS: AN OVERVIEW

1. Sturrock RD: Update on the pathogenesis of rheumatoid arthritis. Int Conger Ser 2006; 1295: 1-8.
2. Breedveld FC. Weisman MH and Kavanaugh AF: The PREMIER Study A multicenter, randomized, double-blind clinical trial of combination therapy with Adalimumab Plus Methotrexate versus Methotrexate alone or Adalimumab alone in patients with early, aggressive Rheumatoid Arthritis who had not had previous Metho.
3. Aazuma Y, Kaji K, Katogi R, Takeshita S and Kudo A: Tumor necrosis factor-alpha induces differentiation of bone resorption by osteoclasts. J Biol Chem 2000; 275:
4858-64.
4. Lillegraven S and Kvien TK: Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 827-40.
5. Feldmann M and Maini RN: Anti-TNF alpha therapy of theumatoidarrtitis; what have we learned. Anna Rev Immanol
2001:19:163-96.
6. Toussirot E and Wendling D: The use of TNF-alpha blocking agents in rheumatoid
arthritis; an overview. Export Open Pharmactober 2004; 5:1-14.
7. Taylor PC, Peters AM and Paleolog E:
Reduction of chemo kine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum
2000:43:38-47.
8. Sarzi-Puttinia P, Arzenia F. Shoenfeldb Y and Fetraccioli G: TNF-alpha, rheumatoid atthritic, and heart failure a rheumatologic dilemma. Antoimmnn Rev
2005; 4:153-61.
9. Wordsworth P and Holden W: Rheumatoid Arthritis. In: John Wiley & Sons, ed. Encyclopedia of Life Sciences.
Chichester: Wiley-Blackwell, 2005; http://
www. els.net / doi: 10: 138/ npg.els. 0004113 (accessed on 7 June, 2010)
10. Moreland LW and Curtis JR: Systemic no articular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Sonin Aretbritis Rbeum 2008:39:132-43.
11. Saklatvala J: Tumor necrosis factor alpha stimulates resorption and inhibitssynthesis of proteoglycan in cartilage. Nature 1986; 322:547.
12. Food and Drug Administration. FDA labeling information.FDA web site on line http//www.accessdata.fda.gov/drugsatfda_d ocs/label/2009/125289s000lbl.pdf.2009
13. Raychaudhari SP, Nguyen CT, Raychaudhauri SK and Gershwin ME: Incidence and nature of infectious disease in patients treated with anti-TNF agents.
Autoimmune Rev 2009; 9:67-81.
14. Krane SM, Conca W, Stephenson ML. Amento OP and Golding MB. Mechanisms of matrix degration in rheumatoid arthritis.
15. Smolen JS and Weinblatt ME: when patients with rheumatoid arthritis fail tumor necrosis factor inhibitors.
16. Geokoop-Ruiterman YPM, de Vries-Bouwstra JK and Allart CF: Clinical and radiographic outocomes of four different treatment strategies in patients with RA.
17. Gerlag DM and Tak PP: Novel
approaches for the treatment of RA, lessons from the evaluation of synovial biomarkers in clinical trials. Best PractClinRbenmatol
2008; 22:311-23.
18. Brennan FM, Chantry D., Jackson A, Maini R and Feldmann M: Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in RA.
19. Zidi I, Mestiti S, Bartegi B and Ben Amor N: TNF-alpha and its inhibitors in
cancer, Med Oncol 2009: DOI:
10:1007/s 1203 2-009-9190-3.
20. Pappas AD, Bathon JM, Hanicq D, Yasothan U and Kirkpatrick P: Golimumab.
21. Elliott MJ, Maini RN and Feldmann M: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
22. Keystone E and Haraoui B: Adalimumab therapy in rheumatoid arthritis and Rheumatism. Rbenm DIs
ClinNortb Am 2004; 30:349-64.
23. Edwrads CKI: PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.
24. Inman RD, Davis JJC and van der Heijde D: Efficacy and safety of Golimumab in patients with ankylosing spondylitis: results of a randomized, double-Blind, placebo-controlled, phase
III trial. Arthritis Rheum 2008; 58: 3402¬12.
25. Hutas G: Golimumab, a fully human monoclonal antibody against TNF-alpha. Curr Opin Mol Ther 2008; 10: 393-406.26. Kavanaugh A. Melnnes I and Mease P: Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection.
27. Netterwald J. TNF-blocker triple approval Nat Brotecbnal 2009; 27:495.
28. Smolen JS, Kay J and Doyle MK:
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor & inhibiters.
29. Food and Drug Administration. Simponi REMS. FDS web site on line, http://www.fda.gov/downloads/safety/Med. Watch/safety information/safety altersforhuman medical products.
30. Food and drug administration. FDA web site online, http://www.fda. gov/News events/newsroom/PressAnnuncemenys/uc m149569, htm.2009.
31. Caporali R, Caprioli M, Bobbio-Pallavicini F and Montecucco C: DMARDS and infections in rheumatoid arthritis. Autoimmun Rev2008; 8:139-43.
32. SimponiTM (golimumab) [prescribing information], Malvern,pa: centocorortho biotech Inc.
33. Cronstein BN: Molecular therapeutics: methotrexate and its mmechanism of action.Arthritis Rhum 1996; 39: 1951-60.
ISSN: 2277-8713
IJPRBS
34. Cutolo M, Sulli A, Pizzroni C, Serilolo B and Straub R: Anti-inflammatory mechanism of methotrexate in rheumatoid
arthritis. Ann. Rhum Dis 2001; 60:729-35.
35. Darlymple JM, StamLk, o'DonnellJl and Chapman PT: Pharmacokinetics of oral methotrexate inpatients with rheumatoid arthritis. Arthritis Rheum;
2008; 58; 3299-308.
36. Shealy D, Cai A, Lacy E and Nesspor T: Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNF-a. Ann rheum Dis 2007; 66 (supply, 2):ii151.
37. Kay J, Matteson EL and DasguptaB: Golimumab in patients with active rheumatoid arthritis despite treatment with rheumatoid arthritis Rheum 2008; 58: 964¬75.
38. Keystone EC, Genovese MC and Klareskog L: Golimumab a human antibody to tumornecrosis factor alpha given by monthly subcutaneous injection, in active rheumatoid arthritis despite methotrexate therapy: Ann Rheum Dis
2009; 68 789-96.
39. Emery P and Fleischmann RM: Golimumab a human antibody to human necrosis factor alpha given by monthly subcutaneous injection, in active rheumatoid arthritis every four weeks inmethotrexate-native patients with active rheumatoid arthritis. 2009; 60:2272-83.
40.
Smole
n J, Kay J and Doyle MK: Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors. Lancet 2009; 374:210-21.
41.
Wenze
l SE, Barrens PJ and bleckeer ER: for the TO3 asthma investigators. A double blind, randomized, placebo controlled study for the tumor necrosis factor alpha blockade in the severe persistent asthma, Am J Respircrit care
MED. 2009;179-549-558.
42.
Simpon
i [package insert]. Horsham, pa: centocorortho biotech Inc; April 2009.
Http://www.simponi.com/sites/default/foles /hcp-files/pdf/prescribing-information. August 31, 2010.
43.
Produc
t information. Simponi (golimumab) horshan, PA: Centocorortho biotech Inc. April 2009.
44.
Cardina
l health, Average wholesale price; 2009 August. WWW. Cardinal.com (accessed 2009 Aug 8).
45.
Smole
n J, Kay J and Doyle MK: Golimumab in patients with active rheumatoid arthritis aftertreatment with tumor necrosis factor alpha inhibitors (Go-after study): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. Lancet 2009:374:210-21.
Available Online